Table 4 Kaplan-Meier estimated sustained ulcer-free rates (95% confidence interval) at 52 weeks, presented by patient subgroup (full analysis set)
Subgroup | Esomeprazole 20 mg once daily (n=130) |
|---|---|
Sex | |
Men (n=35) | 97.0% (91.1, 100) |
Women (n=95) | 95.5% (91.1, 99.8) |
Age | |
≤64 years (n=63) | 96.7% (92.2, 100) |
≥65 to ≤74 years (n=43) | 92.3% (83.9, 100) |
≥75 years (n=24) | 100% (100, 100) |
Helicobacter pylori infection | |
Positive (n=57) | 98.1% (94.3, 100) |
Negative (n=73) | 94.3% (88.8, 99.7) |
Use of corticosteroids | |
Yes (n=32) | 96.7 (90.2, 100) |
No (n=98) | 95.6 (91.4, 99.8) |
Type of NSAID at baseline | |
COX-2-selective (n=21)a | 94.7% (84.7, 100) |
Non-selective (n=109) | 96.1% (92.3, 99.8) |
CYP2C19 genotype | |
Poor metaboliser (n=22) | 95.5% (86.8, 100) |
Hetero extensive metaboliser (n=68) | 93.8% (87.9, 99.7) |
Homo extensive metaboliser (n=40) | 100% (100, 100) |